John Spertus
Cardiovascular Disease · Kansas City, MONPI 1982603973
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $349,991 of the $360,209 with a category attached, or 97.2%. It is spread thinly across 15 manufacturers, the largest accounting for just 21.3%. Reporting peaked in 2023 at $105,059 and has fallen 99.8% since, to $166 in 2025. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 142 payments — averaging $2536.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$77K
- Alnylam Pharmaceuticals Inc.$66K
- E.r. Squibb & Sons, L.L.C.$64K
- Amgen$61K
- Terumo Medical Corporation$30K
- Bayer$25K
- plus $37K from 9 others
Across 119 payments — averaging $16,658 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$711K
- Merck$533K
- Janssen Scientific Affairs, LLC$375K
- Abbott$330K
- Novartis$30K
- Cleerly, Inc.$3K
What the payments were for
- Royalty or licence$3,0001%
- Consulting fees$349,99197%
- Travel & lodging$4,2141%
- Food & beverage$3,0041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 21 | $76,878 |
| Alnylam Pharmaceuticals Inc. | 6 | $65,584 |
| E.r. Squibb & Sons, L.L.C. | 11 | $64,415 |
| Amgen | 26 | $61,394 |
| Terumo Medical Corporation | 31 | $29,818 |
| Bayer | 4 | $25,037 |
| Merck | 9 | $9,300 |
| Sanofi-aventis U.S. LLC | 2 | $8,413 |
| Eli Lilly | 1 | $6,888 |
| Edwards Lifesciences | 9 | $5,693 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $4,500 |
| Abbott | 16 | $1,930 |
| Novartis | 3 | $304 |
| AstraZeneca | 1 | $28 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$72,300
- Non-Covered$24,953
- CAMZYOS$24,600
- MULTAQ$8,413
- ARCALYST$4,500
- XARELTO$4,297
- GLIDESHEATH SLENDER$1,890
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,000
- ONPATTRO$562
- LEQVIO$261
- CARDIOMEMS$163
- Confirm Rx$160
- COROFLOW$154
- ENTRESTO$122
- GlideWire$100
How this compares
$360,209 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Kansas City
- Mikhail KosiborodKansas City$1.1M
- Kyle LehenbauerKansas City$108K
- Deepa UpadhyayaKansas City$58K
- David SkolnickKansas City$44K
- Garth GrahamKansas City$32K
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- James FairlambColumbia$342K
- James EllisonChesterfield$267K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.